KRMD - Breaking The Hospital Chain: Analyst On How KORU's Self-Administered Therapies Promise 20% CAGR Through 2026 | Benzinga
B. Riley has initiated coverage of KORU Medical Systems Inc (NASDAQ: KRMD) with a Buy rating and a price target of $4.50.
The analyst Neil Chatterji notes that KORU Medical's innovative Freedom Infusion System represents a significant advancement in medical treatment by delivering drugs subcutaneously (under the skin).
The system primarily targets the growing subcutaneous immunoglobulin (SCIg) market, valued at approximately $500 million, catering to patients with immunodeficiency and other related conditions.
Moreover, it is poised to transform into a versatile therapy delivery platform, ...